- $20.76m
- $25.63m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.84 | ||
| Price to Tang. Book | 1.86 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -132.35% | ||
| Return on Equity | -233.26% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.56 | n/a | n/a | n/a | n/a | n/a | 7.7 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Directors
- Geert Kersten CEO (62)
- Patricia Prichep SVP (70)
- John Cipriano SVP (78)
- Daniel Zimmerman SVP (79)
- Eyal Talor CSO (64)
- Bruno Baillavoine IND (67)
- Robert Watson IND (63)
- Peter Young IND (76)
- Last Annual
- September 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 22nd, 1983
- Public Since
- December 8th, 1983
- No. of Shareholders
- 465
- No. of Employees
- 43
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NYSE MKT- Shares in Issue
- 84,124,041
- Address
- SUITE 802, 8229 BOONE BLVD ., VIENNA, 22182
- Web
- https://cel-sci.com/
- Phone
- +1 7035069460
- Auditors
- BDO USA, LLP
Upcoming Events for CVM
Q2 2025 CEL-SCI Corp Earnings Release
Q3 2025 CEL-SCI Corp Earnings Release
Q3 2025 CEL-SCI Corp Earnings Release
Similar to CVM
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
Apimeds Pharmaceuticals US
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
Azitra
NYSE MKT
FAQ
What is the CEL-SCI share price?
As of Today at 07:51 UTC, shares in CEL-SCI are trading at $0.25. This share price information is delayed by 15 minutes.
How has the CEL-SCI share price performed this year?
Shares in CEL-SCI last closed at $0.25 and the price had moved by -83.66% over the past 365 days. In terms of relative price strength the CEL-SCI share price has underperformed the S&P500 Index by -84.92% over the past year.
What are the analyst and broker recommendations for CEL-SCI?
The overall consensus recommendation for CEL-SCI is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the CEL-SCI dividend yield?
CEL-SCI does not currently pay a dividend.
Does CEL-SCI pay a dividend?
CEL-SCI does not currently pay a dividend.
When does CEL-SCI next pay dividends?
CEL-SCI does not currently pay a dividend.
How do I buy CEL-SCI shares?
To buy shares in CEL-SCI you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CEL-SCI?
As of the previous close price of $0.25, shares in CEL-SCI had a market capitalisation of $20.76m.
Where are CEL-SCI shares listed?
Here are the trading details for CEL-SCI:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: CVM
What kind of share is CEL-SCI?
Based on an overall assessment of its quality, value and momentum CEL-SCI is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CEL-SCI share price forecast for 2025?
The analyst consensus target price for shares in CEL-SCI is $7.40. That is 2898.38% above the last closing price of $0.25.
Analysts covering CEL-SCI currently have a consensus Earnings Per Share (EPS) forecast of -$0.35 for the next financial year.
Find out moreWhat is the trend in the CEL-SCI share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CEL-SCI. Over the past six months, its share price has underperformed the S&P500 Index by -64.05%.
As of the last closing price of $0.25, shares in CEL-SCI were trading -62.77% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CEL-SCI PE Ratio?
The CEL-SCI PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CEL-SCI?
CEL-SCI's management team is headed by:
- Geert Kersten - CEO
- Patricia Prichep - SVP
- John Cipriano - SVP
- Daniel Zimmerman - SVP
- Eyal Talor - CSO
- Bruno Baillavoine - IND
- Robert Watson - IND
- Peter Young - IND